- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03420677
Enhancement of Sleep With Wearables (WESA)
2. März 2021 aktualisiert von: Swiss Federal Institute of Technology
Enhancement of Sleep Slow Wave Activity Using Wearable Auditory Stimulation Devices and Its Consequences on Daytime Functioning: a Randomized, Counter-balanced Crossover Study
Sleep, specifically deep sleep, plays a central role in healthy brain function, cardio-vascular processes, mood and quality of life.
Auditory stimulation during one night of sleep has previously been shown to improve deep sleep and along with memory formation in both young and older adults.
Yet, it remains unclear whether long-term auditory stimulation considerably improves sleep quality over longer time periods and how it affects daytime functioning such as cognition, mood, quality of life and peripheral functions (e.g.
cardio-vascular).
Due to the importance of deep sleep for brain and body and the presence of many conditions that involve reduced deep sleep (e.g.
ageing) assessing the beneficial impact of long-term sleep enhancement and its consequences is of central interest.This study will assess the effect of auditory stimulation over two weeks (interleaved with a two weeks washout period) in a cohort of healthy young and older adults using portable recording and stimulation devices.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
33
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Zurich
-
Zürich, Zurich, Schweiz, 8092
- Swiss Federal Institute of Technology
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 84 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Informed Consent as documented by signature
- For women: Hormonal contraception, if menstrual cycle is still present or has been present less than a year ago
- Good general health status
- Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study
- Male and Female subjects 18-35 years of age or 60-84 years of age
- German speaking
Exclusion Criteria:
- Women who are pregnant or breast feeding,
- Known or suspected non-compliance, drug or alcohol abuse,
- Intake of sleep altering medication
- Inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits
- Participation in another study with investigational drug within the 30 days preceding and during the present study,
- Presence or history of diagnosed psychiatric/neurologic disorder/lesion of the central nervous system (CNS),
- Diagnosed internal disease,
- Presence of sleep disorders,
- Shift-work (work during the night) or situations that require several awakenings during the night (e.g. newborn)
- Travelling more than 2 time zones in the last month before intervention starts or during intervention (study start will be shifted accordingly)
- Hearing disability/ hearing aid
- Skin disorders/problems in face region that will worsen with /not allow adhesive electrode application
- Nicotine/Cannabis use
- High caffeine consumption (> 5 servings/day; including coffee, energy drink)
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Application of tones
During non-rapid eye movement (NREM) sleep short tones will be played
|
During NREM sleep, tones (max.
60 dB) will be played using a portable, safe, in-home device.
This device records biosignals (e.g.
brain activity) and precisely times the tones during NREM sleep.
It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
|
|
Schein-Komparator: No application of tones
During NREM sleep no short tones will be played
|
This is the sham-control intervention; The device will only record biosignals but will not play tones.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sleep quality
Zeitfenster: From baseline period to study completion, assessed up to 2 months
|
Objective information about sleep macro- and microstructure will be assessed including measures like sleep architecture, amount of slow wave activity (SWA), amount of spindles, awakenings during sleep, and sleep fragmentation.
In addition, subjective sleep quality will be obtained by questionnaires every morning over the intervention period.
These measures will show whether auditory stimulation enhanced overall sleep quality compared to sham.
|
From baseline period to study completion, assessed up to 2 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Daily functioning - Mood
Zeitfenster: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Mood will be digitally assessed using a daily mood scale over the intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
|
Daily functioning - Quality of life
Zeitfenster: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Quality of life will be assessed using a World Health Organization (WHO) quality of life assessment before and after each intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
|
Daily functioning - Vigilance
Zeitfenster: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Vigilance will be assessed using a digital psychomotor vigilance task, assessed daily over the intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
|
Daily functioning - Cognition
Zeitfenster: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Cognition will be assessed using a digital test battery before and after each intervention
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
|
Physiological parameters - Cardiovascular
Zeitfenster: From baseline period to study completion, assessed up to 2 months
|
R-R interval based assessments will be obtained using wearable monitors
|
From baseline period to study completion, assessed up to 2 months
|
|
Physiological parameters - Physical activity
Zeitfenster: Through study completion, approximately 2 months
|
Physical activity levels will be obtained using wearable monitors
|
Through study completion, approximately 2 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Device usability
Zeitfenster: From the first home visit until the end of the second intervention period, assessed within a time period up to 2 months
|
Questionnaires will be used to track specific information about the portable intervention device including information about its usability, discomfort and blinding to the condition
|
From the first home visit until the end of the second intervention period, assessed within a time period up to 2 months
|
|
Diary
Zeitfenster: Through study completion, approximately 2 months
|
Information about daily habits will be digitally assessed
|
Through study completion, approximately 2 months
|
|
Incidence of Intervention-related Adverse Events [Safety and Tolerability]
Zeitfenster: Through study completion, approximately 2 months
|
Any adverse or serious adverse events during the study period will be assessed
|
Through study completion, approximately 2 months
|
|
Chronotype
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of circadian type
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
|
Handedness
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of handedness
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
|
Menstrual cycle
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of menstrual cycle information in woman
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
|
Height
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of height
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
|
Hip-to-waist ratio
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of hip and waist circumference
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
|
Blood pressure
Zeitfenster: Through study completion, approximately 2 months
|
Assessment of blood pressure
|
Through study completion, approximately 2 months
|
|
Weight
Zeitfenster: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of weight
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
7. Mai 2018
Primärer Abschluss (Tatsächlich)
5. März 2019
Studienabschluss (Tatsächlich)
30. Oktober 2020
Studienanmeldedaten
Zuerst eingereicht
4. Dezember 2017
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. Januar 2018
Zuerst gepostet (Tatsächlich)
5. Februar 2018
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
3. März 2021
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
2. März 2021
Zuletzt verifiziert
1. März 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- WESA_2017-01436
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schlafen
-
Haseki Training and Research HospitalNoch keine RekrutierungRichards-Campbell Sleep-Fragebogen (RCSQ)
-
ElsanEuropean Clinical Trial Experts Network; Polyclinique PoitiersAbgeschlossenObstruktives Schlafapnoe-Syndrom | Hypnose | Drug Induce Sleep EndoscopyFrankreich
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityBeendetSchlafstörungen, intrinsisch | Schlaf-Wach-Störungen | Schlafstörungen, zirkadianer Rhythmus | Fortgeschrittenes Schlafphasensyndrom (ASPS) | Verzögertes Schlafphasensyndrom | Schichtarbeits-Schlafstörung | Verzögerte Schlafphase | Nicht-24-Stunden-Schlaf-Wach-Störung | Fortgeschrittenes Schlafphasensyndrom und andere BedingungenVereinigte Staaten
Klinische Studien zur Application of tones
-
Ataturk UniversityAbgeschlossenBrustkrebs | Humanes Papillomavirus | FrauenTürkei (türkiye)
-
King Saud UniversityAbgeschlossenRehabilitation | Muskelkraft | Quadrizeps-MuskelSaudi-Arabien
-
University of MinnesotaZurückgezogen
-
Nova Scotia Health AuthorityZurückgezogenPatuläre Dysfunktion der Eustachischen RöhreKanada
-
Zhuhai Tonbridge Medical Tech. Co., Ltd.Noch keine RekrutierungAkuter ischämischer SchlaganfallChina
-
Sairah SadafAbgeschlossen
-
University Hospital Hradec KraloveThe Society of General Practice, J. E. Purkyne Czech Medical Association; Hospital...Anmeldung auf EinladungHörverlust, bilateral oder einseitig | Hörverlust, beidseitig sensorineural, progressiv | Presbyakusis | Hörverlust, bilateral (andere Ursachen als Tumore)Tschechien
-
Anjali Raja BeharelleMediService AGAbgeschlossenHypertonie | MedikamentenhaftungSchweiz
-
Xijing HospitalRekrutierung
-
Aalborg UniversityNoch keine RekrutierungGesund | SchleudertraumaDänemark